Zepbound's path to public coverage

What happened

On 3 September 2026 the pCPA sent Eli Lilly Canada Inc. a letter of acknowledgement for Zepbound. The pCPA is the group that negotiates drug prices for the provincial, territorial and federal public drug plans. Its page for Zepbound, file 78166, gives the status as “Under consideration for negotiation”. The next step on that page is a letter of engagement, which tells the manufacturer the pCPA is ready to start negotiating. The page shows no date for it.

The letter follows a recommendation from Canada’s Drug Agency (CDA-AMC), the national body that assesses drugs for public plans. CDA-AMC published its final recommendation for Zepbound on 28 August 2026. It recommended that public plans reimburse Zepbound for chronic weight management under these conditions:

• The person is an adult with a body mass index (BMI) of 27 or higher and prediabetes, meaning blood sugar that is higher than normal but not yet in the diabetes range.
• The person has made at least one self-reported unsuccessful attempt to lose weight through diet.
• The person is following a reduced-calorie diet and increasing physical activity.
• The price of Zepbound is reduced.
• After the first year, continued reimbursement needs a minimum weight reduction from the starting point, set by the agency and documented. The person is then reassessed each year.
• Zepbound is not reimbursed together with other GLP-1 medications.

The renewal criterion is a coverage rule the agency set. We report it as a rule and don’t draw conclusions from it about any medication.

Date	Step	Drug
24 Aug 2026	CDA-AMC publishes its recommendation	Mounjaro
28 Aug 2026	pCPA sends letter of acknowledgement	Mounjaro
28 Aug 2026	CDA-AMC publishes its recommendation	Zepbound
3 Sep 2026	pCPA sends letter of acknowledgement	Zepbound

Mounjaro is the other tirzepatide product from Eli Lilly. It is for adults with type 2 diabetes, and CDA-AMC recommended it with conditions on 24 August 2026. The pCPA lists it with the same status as Zepbound.

What it means in Canada

Health Canada has authorized Zepbound, so a prescriber can write a prescription and you can fill it now. See Zepbound cost in Canada for what builds the price. Public coverage is a separate path. The pCPA describes it in four steps, and a recommendation is only the second.

1. Regulatory review. Health Canada checks a drug’s safety, efficacy and quality and authorizes it for sale.
2. Health technology assessment. CDA-AMC (or Quebec’s own agency, INESSS) looks at clinical benefits, cost-effectiveness and system impact. It recommends yes or no, with conditions such as who is eligible or a lower price. The recommendation helps public plans decide. It does not create coverage by itself. We haven’t checked what INESSS has decided for Zepbound.
3. Price negotiation. After a positive recommendation, the pCPA sends the manufacturer a letter of acknowledgement. During consideration, public plans confirm whether they want to take part and the pCPA gathers evidence. It then tells the manufacturer whether it will negotiate, hold the file or close it. If it negotiates, the two sides exchange offers. A deal ends in a letter of intent that sets the price and other terms, such as who is eligible. No deal ends in a close letter.
4. Listing. Each province, territory and federal plan decides for itself. It signs a product listing agreement with the manufacturer, and only then may it add the drug to its formulary, the list of drugs the plan agrees to pay for. Plans often list a drug with conditions your prescriber must show you meet, called special authorization, Limited Use or something similar.

Zepbound is at the start of step 3.

A positive recommendation doesn’t mean a listing will follow. BC PharmaCare’s decision of 18 December 2025 on Wegovy says the pCPA concluded negotiations on 1 December 2025 without agreement, notes that the manufacturer declined negotiations, and lists Wegovy as a non-benefit. That is a different drug and manufacturer. We aren’t predicting an outcome for Zepbound.

What hasn’t changed

Nothing in the pCPA’s letter changes what you pay today. We haven’t found a provincial, territorial or federal public plan that lists Zepbound for weight management, and the pCPA page shows no negotiation dates. Our coverage page shows what we have confirmed by province, and the Ontario page says where Ontario stands.

Employer plans are separate. The CDA-AMC recommendation and the pCPA talks are about public plans, and your employer plan sets its own rules.

If you have an employer plan

1. Ask your insurer or benefits administrator whether the plan covers weight-management drugs at all.
2. Ask whether Zepbound needs prior authorization. That means your prescriber sends the insurer a form before it pays. Ask what the form requires and who submits it.
3. Ask whether the plan has a yearly or lifetime limit.
4. Ask whether the plan pays for a generic when one exists. Our generics page lists approved generic semaglutide products only, so it doesn’t answer this for Zepbound.
5. Ask your pharmacist for the full price with the dispensing fee, so you know what you would pay if a request is refused.

What happens next

The next step to watch is the pCPA’s letter of engagement. After consideration, the pCPA sends the manufacturer a letter saying whether it will negotiate, hold the file or close it. If it negotiates, the Zepbound page should show the date, followed by the milestones for negotiations starting, terms reached and the process concluding.

The pCPA says it aims to finish standard negotiations within 90 business days of the letter of engagement, and that many factors affect timing. No letter of engagement is posted for Zepbound, so we won’t estimate a date.

Even after a letter of intent, each public plan makes its own listing decision. Check your province’s plan on our coverage pages, and see Zepbound cost in Canada for what you can do today.